

2018 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Austin, TX – March 10, 2018

Conference Location	Hilton Austin Airport 9515 Hotel Drive Austin, Texas, 78719	Phone: 512-385-6767 http://www3.hilton.com/en/hotels/texas/hilton-austin-airport-USAHHF/index.html
----------------------------	--	--

Parking at the Conference Reduced parking for all participants is available for \$10.

- Driving Directions**
- **From the South:** IH 35 North to Highway 71 East. Exit Airport Cargo Exit. Turn right at Spirit of Texas Drive/Terminal Drive and left at Hotel Drive.
 - **From the North:** IH 35 South to 183 South to Highway 71 East. Exit Airport Cargo Exit. Turn right at Spirit of Texas Drive/Terminal Drive and left at Hotel Drive.
 - **From the East:** HWY 71 West to Airport/Airport Cargo Exit, turn left at Spirit of Texas Drive/Terminal Drive and left at Hotel Drive.
 - **From the West:** HWY 71 East to Airport/Airport Cargo Exit, turn right at Spirit of Texas Drive/Terminal Drive and left at Hotel Drive

Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the **Chenault Room foyer**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00am	Welcome and Pre-Test
8:20 am	<p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease <p>Liver Transplantation</p> <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions <p>Case Study 1 – Cirrhosis and Encephalopathy</p>
9:20 am	<p>Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	<i>Break & View Exhibits</i>
10:15 am	<p>Hepatocellular Carcinoma: New Systemic Treatment Options</p> <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC <p>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</p>

11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:40 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid Case Study 3 - PBC with inadequate response to Ursodiol
12:00 pm	Lunch & View Exhibits
12:30 pm	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:00 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
1:45 pm	Break & View Exhibits
2:00 pm	NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 4 - NASH Diagnosis and Treatment
3:00pm	Post-test
3:15 pm	Adjourn

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1014. The Kentucky Board of Nursing

approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your
Seminar
Faculty**



IMTIAZ ALAN, MD

Imtiaz Alan received his medical degree from University of Dundee in Scotland. He completed his residency at Hahnemann University Hospital, PA and his gastroenterology and hepatology fellowship at the University of California, San Francisco.

In 2014, Dr. Alan started the HepCare Specialty Pharmacy dedicated to providing pharmacy services to the hepatitis C patient. Dr. Alan maintains one of the largest private practices in the country devoted to chronic liver diseases.

Dr. Alan is board certified in Internal Medicine and Gastroenterology. He is a Clinical Associate Professor of Medicine at both at Dell Medical School, University of Texas, Austin and Texas A&M University. He is currently a principal investigator for many Phase 2 to 4 clinical drug trials. He has written and published numerous articles.



SAIRA A. KHADERI, MD, MPH

Dr. Saira A. Khaderi is Assistant Professor of Surgery in the Division of Abdominal Transplantation of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. She is also the assistant director of ECHO Texas, a program that partners Baylor faculty with medical providers in rural and underserved communities.

Dr. Khaderi earned her medical degree from The University of Texas Medical Branch in Galveston and her Master's in Public Health from The University of Texas School of Public Health in Houston, Texas. Her clinical interests include transplant, hepatitis C, cirrhosis and end-stage liver disease..



SHADI GIANI, APRN, ACNS

Shadi Giani received her undergraduate and graduate degrees from the University of Texas at Austin. She spent the majority of her time in school training in gastroenterology and hepatology.

Upon graduating with a Master of Science in Nursing degree, she began working full-time at Austin Hepatitis Center. She is recognized by the Board of Nurse Examiners as an Advanced Practice Registered Nurse with diagnostic and prescriptive authority, and is board certified as an Adult Health Clinical Nurse Specialist.
